Upcoming market catalysts for the first quarter of 2026 include US approval decisions on clemidsogene lanparvovec (also known as RGX-121) for the treatment of mucopolysaccharidosis type II (MPS II), dibutepinephrine for the treatment of severe allergic reactions and tabelecleucel for the treatment of Epstein–Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Enjoying our latest content?
Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research
Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD